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Continuous delivery of drugs to the eye offers major advantages over conventional
therapies that involve administration of drug solutions or suspensions as eye drops. Eye
drop administration often results in poor bioavailability and therapeutic response due to
rapid precorneal elimination of the drug and is also associated with patient compliance
problems (1, 2). For this reason, several approaches have been reported and various oph-
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Pefloxacin mesylate is a flouroquinolone antibacterial drug
effective in the treatment of bacterial conjunctivitis. The ob-
jective of the present work was to develop ocular inserts of
pefloxacin mesylate and evaluate their potential for sus-
tained ocular delivery. Reservoir-type ocular inserts were
prepared by the film casting technique in teflon coated
Petri dishes and characterized in vitro by drug release stud-
ies using a flow-through apparatus that simulated the eye
conditions. Six formulations were developed, which dif-
fered in the ratio of polymers Eudragit RS 100 and Eudra-
git RL 100 used for the preparation of the rate controlling
membrane. All formulations carried 0.72 mg pefloxacin
mesylate, 2.69 mg polyvinyl pyrrolidone (PVP) K-30, pla-
sticizers, propylene glycol (10% m/m) and dibutyl phthala-
te (15%, m/m). The optimized formulation was subjected to
microbiological studies, in vivo studies, interaction studies,
and stability studies to assess the effectiveness of the for-
mulation. Cumulative drug released from the formulation
ranged from 90–98% within 48 to 120 hours.
On the basis of in vitro drug release studies, the formula-
tion with Eudragit RS 100/Eudragit RL 100 (4:1) was found
to be better than the other formulations and it was selected
as an optimized formulation. On the basis of in vitro, mi-
crobiological, in vivo drug release, interaction and stability
studies, it can be concluded that this ocular insert formula-
tion provided the desired drug release in vitro for 5 days
and remained stable and intact at ambient conditions.
Keywords: pefloxacin mesylate, ocular insert, in vitro re-
lease studies, in vivo studies
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thalmic vehicles, such as suspensions, ointments, inserts and aqueous gels, have been
investigated to extend the ocular residence time of topically applied medications (3).
Ophthalmic inserts offer many advantages over conventional dosage forms, like increased
ocular residence, possibility of releasing drugs at a slow and constant rate, accurate dos-
ing, exclusion of preservatives and increased shelf life (4–6). Moreover, the use of these
devices reduces systemic absorption, which otherwise freely occurs with eye drops. It
also ensures better patient compliance due to lower frequency of administration and
lower incidence of side effects (7–9). Baeyens et al. (10) developed soluble bioadhesive
ophthalmic drug inserts for the treatment of external ocular diseases such as conjunctivi-
tis, keratoconjunctivitis sicca and superficial corneal ulcers. Sasaki and co-researchers (11)
prepared a unique one-side-coated insert that releases drug from uncoated side only.
Ocular application of the one-side-coated insert produced constant concentrations of tili-
solol in the tear fluid over 180 min.
The aim of this study was to prepare ocular inserts of pefloxacin mesylate (PM) and
to demonstrate sustained antimicrobial action in vitro for 5 days.
EXPERIMENTAL
Pefloxacin mesylate (by courtesy of Ranbaxy Research Labs, India), polyvinyl pyr-
rolidone (PVP K-30) (Dabur, India), Eudragit RL 100 and Eudragit RS 100 (Pharmax, In-
dia), propylene glycol (C.D.H, India), silica gel (E.Merck India Ltd., India) and dibutyl
phthalate (S.D. Fine Chemicals Ltd, India) were used. The reference standard of the drug
was from Cipla Ltd. (India). All solvents were of analytical grade.
Preparation of ocular inserts
The preparation of ocular inserts involved three steps: (i) preparation of the drug-
-containing reservoir film of PVP K-30, (ii) preparation of rate controlling films of Eu-
dragit, (iii) placing rate controlling films around the drug reservoir and sealing them to
obtain ocular inserts.
For preparation of the drug-containing reservoir film, polymeric solutions were pre-
pared by dissolving 1.0, 1.5, 2.0, 3.5 and 4.0% of PVP K-30, along with 0.38% (m/V) of
pefloxacin mesylate (PM) and propylene glycol (10%, m/m), in doubly distilled water
(film codes A, B, C, D and E). The solutions were poured into a glass ring of 5.5 cm di-
ameter placed in a Teflon coated Petri dish. The solvent was allowed to evaporate by
placing it inside an oven maintained at 35  2 C, 30  0.5% RH for 24 h.
To prepare the rate-controlling films, Eudragit RS 100 and Eudragit RL 100, in the ratio
of 1:1, 1.6:1, 3:1, 4:1, 5.6:1 and 9:1 (in formulations a, b, c, d, e and f, respectively along
with 15% (m/m) of plasticizer, dibutyl phthalate were dissolved in ethanol/acetone (80:20)
mixture. Final concentration of Eudragits RS and RL, and dibutyl phthalate were 4.0%
and 0.6%, respectively. The solutions were poured into a glass ring of 5.5 cm diameter
placed in a teflon coated Petri plate. The solvent was allowed to equilibrate at 25  0.5
C, 45  0.5 % RH for 24 h.
Elliptically shaped ocular inserts were cut out of medicated reservoir film with the
help of a stainless steel die. These ocular inserts were placed on a rate-controlling mem-
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brane and another rate controlling membrane was kept over it. The two rate-controlling
membranes containing the reservoir film between them were placed over a beaker satu-
rated with ethanol/acetone vapours (60:40) for 1–2 minutes. This procedure resulted in
sealing the two rate-controlling membranes containing the medicated reservoir film be-
tween them. The final ocular inserts consisted of three films (mass: 8.83  0.0081 mg
(n = 6); length: 13.2  0.0050 mm; width: 5.8  0.0065 mm; thickness: 0.184  0.0081 mm).
Each ocular insert contained 0.72 mg of the drug. The ocular inserts were stored in an
airtight container under ambient conditions.
In vitro drug release studies
A flow-through apparatus designed for in vitro release studies on ocular inserts was
modified (12). The apparatus consisted of a jacketed 250-mL capacity conical flask, jack-
eted flow-through cell, magnetic stirrer, peristaltic pump, a flow regulator device and a
constant-temperature water bath. The ocular insert was placed in the jacketed cell. The
dissolution medium was isotonic phoshate buffer (IPB) of pH 7.4 and the apparatus was
equilibrated at 37  0.5 C. The flow rate of IPB through the jacketed cell was regulated
to 0.4 mL min–1 and samples were withdrawn at appropriate time intervals up to 120 h
and analyzed at 273 nm spectrophotometrically (Beckman DU-64 spectrophotometer, USA).
The in vitro release studies were done on reservoir films A, B, C, D and E (Fig. 1).
The ocular inserts were prepared with the drug reservoir, which showed maximum drug
release (code B), and two rate-controlling membranes. These ocular inserts (code X-1, X-2,
X-3, X-4, X-5 and X-6) were subjected to in vitro release studies (Fig. 2).
Interaction studies
Interaction studies were conducted on the optimized formulation (X-4) by compar-
ing it with the pure drug and the placebo formulation (without drug) on the basis of the
assay, ultraviolet, infrared and thin layer chromatography analyses.
The optimized ocular insert of the drug was powdered in the mortar and extracted
with IPB (pH 7.4). The extract was transferred to the volumetric flask of 50 mL capacity
and made to the volume. It was then filtered through Whatman filter paper No. 42. The
absorbance of the filtered solution was determined spectrophotometrically.
The solutions of pure drug, medicated and placebo formulations were prepared in
IPB of pH 7.4 and filtered through Whatman filter paper No. 42 and scanned for UV ab-
sorption between 200 and 400 nm.
The IR absorption spectra of the pure drug, medicated and placebo formulations
were taken in the range of 400–4000 cm–1 by KBr disc method using IR spectrophoto-
meter (Hitachi, Japan).
TLC analysis was conducted according to BP 2000 (13). Silica gel (1 mm thick, E.
Merck India Ltd., India) plate was used as the stationary phase and the mobile phase
consisted of water/ammonia/butanol/acetone in the ratio of 1:2:4:13. Solutions of pure
drug, medicated formulations (0.38%) and placebo were compared with the drug refer-
ence standard. The depth of thin layer was 2.5 cm. For visualization, a solution of bro-
mocresol purple in 50% (V/V) alcohol (0.4 g L–1) was used as spray reagent and the plate
was observed under UV light.
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Stability studies
Stability studies were conducted according to ICH guidelines (14) by storing repli-
cates of the ocular inserts at 40  0.5 C and 75  5% RH for 6 months. The samples were
withdrawn on days 0, 30, 60, 90 and 180 and analyzed by HPLC (Shimadzu, Japan). The
column was C18 Finepak (particle size 10 micrometers).
The mobile phase consisted of 0.025 mol L–1 phosphoric acid and acetonitrile (85:15).
The solution pH was adjusted between 2.8 to 3.0 with triethylamine. Flow rate was ad-
justed to 2 mL per minute and the eluent was monitored at 278 nm (UV detector). Under
these conditions, the retention time for pefloxacin mesylate was 5 min.
The ocular insert was taken out off the package, ground with 1 mL of water for
HPLC in a mortar, filtered through 0.22 m membrane filter and 20 L of filtrate con-
taining 0.0144 mg of drug was injected into the chromatographic system. The quantity of
drug was estimated from the calibration curve.
In vivo studies
Approval for the use of animals in the study was obtained from the Jamia Hamdard
Animal Ethics Committee (Hamdard University, New Delhi, India). New Zealand rab-
bits of either sex weighing 2.8 to 4.1 kg were used to measure the in vivo release of the
drug in the eye. The rabbits were housed singly in restraining boxes during the experi-
ment and allowed food and water ad libitum. Free leg and eye movement was allowed.
There were 9 animals in the experimental group and 3 animals in the control group.
Both eyes of the control group animals received normal saline. The ocular inserts were
inserted in both eyes of all animals in the experimental group. Three ocular inserts were
removed after each 24 hours from eyes of animals of the experimental group. This was
repeated for 5 days, namely at each 24-h timepoint. The amount of drug remaining in
each ocular insert was determined as per the assay method of drug in ocular inserts
given in interaction studies. Cumulative percent drug released in vivo was calculated.
Microbiological studies
The optimized ocular insert was evaluated microbiologically for controlled drug re-
lease for 5 days. The test microorganisms were E. coli (460  107 cfu) and S. aureus (450 
107 cfu). The clinical isolates of the bacterial species were procured from the Patel Chest
Research Institute (Delhi, India). A layer of seeded agar (10 mL) was allowed to solidify
in the Petri plate. An ocular insert was removed from the pack and carefully placed over
the agar layer and a second layer of seeded agar (10 mL) was applied to cover the insert.
After solidification, the Petri plate was incubated in inverted position for 24 h at 37  0.5
C. After incubation, the length, width and area of zone of inhibition were measured
around the ocular insert. Then the same insert was transferred to a fresh plate seeded
with microorganisms and a second layer of seeded agar was applied to cover the insert.
The same procedure was repeated for 5 days, i.e., by transferring the same insert to a
fresh Petri plate at an interval of 24 h. Normal saline served as a negative control.
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RESULTS AND DISCUSSION
The reservoir type of the ocular insert consisted of three layers of films, the inner
reservoir film containing the drug and two-rate controlling films surrounding the reser-
voir. The ocular inserts are composed of a central reservoir of drug enclosed in specially
designed semipermeable or microporous membranes that allow the drug to diffuse from
the reservoir at a precisely determined rate. For the preparation of the drug containing
reservoir film, PVP K–30 was chosen as the polymer. Propylene glycol used as plasti-
cizer was found to be compatible with the drug and PVP K-30. Best films were obtained
when the plasticizer concentration was 10% (m/m) of the dry mass of the polymer. The
content of the drug of 20 ocular inserts was estimated to be 0.72  0.0003 mg.
To prepare rate controlling films, combinations of Eudragit RS 100 and RL 100 were
assayed in different ratios and dibutyl phthalate was chosen as plasticizer. Flexible, uni-
form and transparent films were obtained containing 15% (m/m) of plasticizer per dry
mass of polymer.
The in vitro release studies were performed using the drug reservoir (without rate-con-
trolling membranes, code A, B, C, D and E). The drug reservoir that showed a fast drug re-
lease rate was chosen for the preparation of final ocular inserts. The fastest release rates
were observed in the case of reservoir code B (Fig. 1). Therefore, code B was selected as the
drug reservoir and it was sandwiched between two rate-controlling membranes (codes a, b,
c, d, e and f) to make the final ocular inserts (codes X-1, X-2, X-3, X-4, X-5 and X-6). Ocular
inserts X-1, X-2, X-3, X-4, X-5 and X-6 were subjected to in vitro release studies (Fig. 2).
For in vitro drug release studies, the slope(s) of the log (percent drug release) vs. log
(time) plots were calculated from the fitted linear regression lines. A slope of 1.0 indi-
cates zero order release kinetics, while a slope of 0.5 indicates diffusional square-root-
-of-time kinetics (14).
Drug release from the drug reservoir code D follows the first order kinetics R =
0.9939, k = 0.0051, t = 15.622 (tabular t at p = 0.05, two tails, df = n–2, is 3.182), which in-
dicates that the drug release from the reservoir is proportional to the amount of drug re-
maining in its interior.
309
































Fig. 1. Cumulative drug released vs. time from drug reservoirs. Mean + SD are presented (n = 3).
The ocular insert that showed maximum drug release for 120 h was selected. As
shown in Fig. 2, 99.0% cumulative drug was released from formulation X-1 (48 hours),
98.6% from formulation X-2 (72 hours), 98.0% from formulation X-3 (96 hours), 98.0%
from formulation X-4 (120 hours), and 90.0% from formulation X-5 (120 hours). Hence,
formulation X-4 was selected as the optimized formulation. The drug was released from
all ocular insert formulations according to zero order kinetics (k = 0.8 to 1.2, Table I). In
order to understand the drug release mechanism from the optimized formulation, the
release data were tested assuming common kinetic models (Table II). For the optimized
formulation X-4, the best-fit kinetic model was the zero order kinetic model (R = 0.9996,
k = 0.3422). There was no sufficient linearity for the diffusion model, Hixon Crowell and
first-order kinetic models. The drug release from such system is controlled by the dissolu-
tion fluid permeating through the membrane until a sufficient internal pressure is reached
to drive the drug out of the reservoir.
A relationship was found between the polymer (type and concentration) and the
rate of release. The release rates were found to decrease by increasing the concentration
of Eudragit RS 100 and decreasing the concentration of Eudragit RL 100 in rate-control-
ling membranes in formulations X-1 to X-5. This might be due to the lower permeability
of Eudragit RS 100 and higher permeability of Eudragit RL 100. Formulation X-4 was
found to be better, since constant and complete release of drug was observed up to 120 h.
310





































Fig. 2. Cumulative drug released in vitro vs. time from ocular inserts. Mean + SD are
presented (n = 3).
Table I. Release of pefloxacin mesylate from ocular inserts in isotonic phosphate buffer pH 7.4 (37 °C)
Code k  SDa p
X-1 1.24  1.01b < 0.0001
X-2 1.14  0.06b < 0.0001
X-3 0.97  0.01b 0.0132
X-4 0.95  0.01 –
X-5 0.89  0.01b 0.0002
a k-slope of log percent drug released vs. log time, n = 3.
b Significantly different with respect to rate constant of X-4.
Drug and polymers were found to possess different max values. The polymer solu-
tions did not show absortion at wavelengths other than their max, suggesting that poly-
mers do not interfere with UV determination of the drug.
Interaction studies were carried out to ascertain any kind of interaction of the drug
with the excipients used in the formulation of ocular inserts. For this purpose, the opti-
mized formulation X-4, placebo formulation and the pure drug were subjected to the as-
say, UV, IR and TLC analyses. The principal spot in TLC obtained with the test solution
was similar in position, colour and size to the chromatogram obtained with the reference
standard of the drug.
Rf value of 0.54 was obtained with the medicated formulation and drug reference
standard. The UV absorption maximum for the pure drug and the medicated formula-
tion was found to be at 273 nm. The spectra recorded were taken as qualitative in order
to assess the change in peaks, pattern of curve, etc. No major differences were observed
in the IR spectra of the pure drug and the medicated formulation. The IR spectrum of
the pure drug and the medicated formulation showed characteristic absorption bands
for carboxylic group (3500, 3400 cm–1), carbonyl group in a six membered ring (1722
cm–1), unsaturation (1635 cm–1) and bands for aromatic rings (1480, 895, 855, 810 cm–1).
The UV and IR spectra of the placebo formulation showed absorption profiles exclusive
of those for the pure drug and medicated formulations. On performing the assay, 99.14%
 0.01% (n = 6) of the drug was recovered from the medicated formulation. The results of
the assay, UV, IR and TLC analyses indicated that there was no chemical interaction be-
tween the drug and the excipients in the ocular inserts.
A very low degradation rate constant (k1 = 6.909  10–5 days–1) was observed on
performing the stability studies according to ICH guidelines (15). It could be assumed
that negligible degradation occurred, and a shelf life of 2 years could be assigned to the
ocular insert.
In vivo drug released from the ocular insert was observed for 5 days by placing the
ocular insert in the rabbit eye and removing it after every day for 5 days for determina-
tion of drug content. Cumulative drug released in vivo vs. time showed a straight line
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t at p = 0.05 (two tails), df = n–2: 2.365
(Fig. 3). It was concluded that drug release in vivo occurred by zero order n = –0.8417,
t-test = 3.118 (tabular t at p = 0.05, 2 tails, df = n–2, is 2.776. Scatter diagram between in
vitro and in vivo release showed high correlation (R = 0.998).
The optimized ocular insert showed antimicrobial activity when tested microbiolo-
gically on solidified agar (Table III). The controlled release of the drug from ocular insert
was observed for 5 days.
CONCLUSIONS
Reservoir type ocular insert consisting of a polyvinyl pyrrolidone reservoir with
pefloxacin mesylate and rate-controlling membranes of Eudragit RS 100 and Eudragit
RL 100 mixtures demonstrated sustained release of the drug in the eye for 5 days. The in
vivo results suggest that the lower hydrophilicity of rate-controlling membrane plays an
important role in retarding the release of the drug from reservoir ocular inserts. The
drug remained intact and stable in the ocular insert in storage, with no apparent chemi-
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Fig. 3. Cumulative drug released in vivo vs. time from ocular inserts. Mean  SD
are presented (n = 3).
Table III. In vitro inhibition of the growth of microorganisms by an optimized ocular inserta
Day
Area of zone of inhibition (mm2)






a An optimized ocular insert is that which showed the maximum drug release for the intended period of time,
i.e., 120 hours (5 days), n = 3.
cal interaction between the drug and the excipients. Further work is in progress to estab-
lish the therapeutic utility of these systems by pharmacokinetic and pharmacodynamic
studies in human beings.
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S A @ E T A K
Okularni umeci za kontrolirano osloba|anje pefloksacin mesilata:
Priprava i ispitivanja
YASMIN SULTANA, MOHAMMAD AQIL i ASGAR ALI
Pefloksacin mesilat je fluorokinolonski antibakterijski lijek u~inkovit u lije~enju bak-
terijskog konjunktivitisa. Svrha ovog rada bila je razviti okularne umetke pefloksacin
mesilata s kontroliranim osloba|anjem ljekovite tvari. Okularni umeci tipa spremi{nih
sustava pripravljeni su lijevanjem filma u Petrijevu zdjelicu oblo`enu teflonom. Ispitano
je osloba|anje pefloksacina in vitro u ure|aju koji simulira uvjete u oku. Razvijeno je {est
pripravaka koji se me|usobno razlikuju po udjelu Eudragita RS 100 i RL 100 upotreb-
ljenog u pripravi membrane koja kontrolira osloba|anje. Sve formulacije sadr`avale su
0,72 mg pefloksacin mesilata, 2,69 mg polivinil pirolidona (PVP) K-30, plastifikatore, pro-
pilen glikol (10% m/m) i dibutil-ftalat (15%, m/m). Provedena su mikrobiolo{ka ispitivanja
te in vivo ispitivanjima interakcija i stabilnosti. Ukupno se iz pripravaka oslobodilo 9098%
ljekovite tvari u razdoblju od 48 do 120 h. Ispitivanja su pokazala su da je pripravak s ud-
jelom RS 100/RL 100 (4:1) najprihvatljiviji. Tim oblikom okularnog umetka postignuto je
in vitro osloba|anje pefloksacina tijekom 5 dana. Za to vrijeme pripravak je stabilan u
ambijetalnim uvjetima.
Klju~ne rije~i: pefloksacin mesilat, okularni umetak, in vitro osloba|anje, in vivo ispitivanja
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